Pediatric Sales Specialist

Avricore grants options. VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) - AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company's board of directors has approved the granting of stock options (the "Options") exercisable for a total of 3,300,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.06 per common share. All Options were granted pursuant to the Company's stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange. The options shall vest quarterly commencing on the date of grant. The options expire 5 years from the date of the grant, subject to the optionees continuing to act as directors, officers, employees or consultants of the Company. Avricore's wholly-owned subsidiary, HealthTab Ltd, recently entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott's point-of-care testing products through the HealthTab(TM) platform in the UK (news release dated August 20, 2026). HealthTab(TM) at the Core of Scalable, Integrated PoCT HealthTab(TM) provides a complete, turnkey solution underpinning national pharmacy-based PoCT networks, including best-in-class instruments, consumables, onboarding, training, and ongoing support for participating sites. At its centre is a secure cloud-based platform that seamlessly connects point-of-care analyzers, patient results, QC data, and pharmacist workflows, creating a unified digital infrastructure for community-based testing. This integrated approach ensures quality-assured testing, consistent data capture across locations, and real-time analytics to support public-health reporting and performance monitoring, while reducing implementation complexity for pharmacy partners. Commitment to Quality and Accuracy HealthTab(TM) is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories. This includes centralized lot monitoring of reagents, mandated internal quality control, and regular external quality-assessment (EQA) events, ensuring that results generated across every participating pharmacy are accurate, traceable, and consistent with internationally recognized reference standards. About Avricore Health Inc. Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab(TM), a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. Avricore Health Inc. Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the planned expansion of the HealthTab(TM) platform across UK pharmacy sites; the anticipated benefits of the collaboration with Abbott; the expected deployment of additional test assays; projected site deployment targets; and the Company's growth strategy in the UK. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: the ability of the parties to perform their obligations under the Agreement; failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Dexcom and Abbott await Medicare CGM coverage expansion for non-insulin diabetes patients. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. Two of the biggest names in diabetes technology - Dexcom and Abbott - are closely monitoring an anticipated Medicare CGM coverage expansion that could open access to continuous glucose monitors for millions of Americans with Type 2 diabetes who do not use insulin. A major policy shift on the horizon. Currently, Medicare coverage for continuous glucose monitors is restricted to individuals with Type 1 or Type 2 diabetes who either take insulin or have a documented history of problematic low blood sugar episodes. The Centers for Medicare and Medicaid Services is expected to broaden this coverage to include people with diabetes who do not take insulin - a move that both companies have indicated could meaningfully reshape the landscape for glucose monitoring in the United States. Dexcom CEO Jake Leach addressed the anticipated policy update during the company's late July earnings call, stating that the company expects to receive a response from the CMS before the end of the year, with coverage anticipated to go into effect by mid-2027. Scale of the opportunity for Dexcom. Dexcom estimates that approximately 25 million people in the United States have Type 2 diabetes and do not take insulin. Of that group, Leach noted that roughly half are of Medicare age. He described the CMS decision as having "the potential to completely reshape diabetes care in the U.S." To support the coverage expansion, Dexcom presented findings from a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions. The 26-week study demonstrated that participants using a CGM achieved a larger hemoglobin A1C reduction compared to a control group and spent five more hours per day within a normal glucose range. Dexcom reported second-quarter sales of $1.31 billion, reflecting a 13% increase year over year. Abbott's preparation and outlook. Competitor Abbott is equally positioned to benefit from the planned Medicare CGM coverage expansion. During Abbott's July earnings call, CEO Robert Ford told investors that the company expects the U.S. Type 2 expansion to make approximately 10 million additional Medicare recipients eligible for coverage, while also driving broader commercial insurance uptake. Ford confirmed that Abbott is actively preparing its sales force, distribution networks, and related resources ahead of the anticipated decision. "This could be a multibillion-dollar opportunity, and it could happen in the fall," Ford said. "I just can't forecast... when exactly it's going to happen." Abbott's diabetes care segment reported sales of $2.19 billion for the quarter, a 10.5% increase compared to the same period the prior year. With both Dexcom and Abbott reporting strong quarterly results in their respective diabetes care segments and preparing for what could be a significantly expanded patient base, the industry is keeping a close watch on CMS timelines. The Medicare CGM coverage decision, expected before year-end, is widely seen as a consequential development for the continuous glucose monitors market and for the broader diabetes management sector in the United States. Hospital & Healthcare Management brings together the global healthcare industry - from hospital administrators and clinical directors to health technology innovators and policy leaders - through trusted editorial, market intelligence, and digital engagement. Its 2026 Media Pack offers integrated solutions to reach your audience: * Magazine & Digital Editions Showcase your brand within premium healthcare industry coverage read by executives and decision - makers worldwide. * Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global hospital and healthcare management value chain. * Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call